AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02078128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral sugar powder
Description: 30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Study NCT02430116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Description: In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
Study NCT02430116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic postconditioning
Description: In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
Study NCT00216216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV q 3 weeks
Study NCT02679170 — intervention group
Intervention type: DRUG
Intervention: Crizotinib
Description: Treatment with crizotinib following routine clinical practice
Study NCT00805324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: desloratadine syrup; 5.0 mL once daily for 28 days
Study NCT01675882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
Study NCT01675882 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin Placebo
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
Study NCT02226211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air-Q intubation laryngeal airway
Description: The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet .
Study NCT02226211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu-Aura i laryngeal mask
Description: The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT.
Study NCT02779244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Weight bearing + Cam Boot
Description: Patients will be transitioned to weight bearing as tolerated in a cam boot.
Study NCT02779244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Weight Bearing + Cam Boot
Description: Subject will be transitioned to non weight bearing cam boot, standard treatment.
Study NCT02785068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151
Description: Oligoclonal antibody
Study NCT02785068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Description: Nanoliposomal irinotecan
Study NCT04364178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus Specific T- Lymphocytes
Description: Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
Study NCT04364178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus Specific T-Lymphocytes
Description: Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
Study NCT03810716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Platform
Description: The participants will see the interactive platform.
Study NCT02785068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: folinic acid
Study NCT02785068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Chemotherapy
Study NCT03360799 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01875978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytosterols & placebo
Description: Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
Study NCT02486874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoreSkin
Description: a human acellular dermal matrix
Study NCT05436730 — intervention group
Intervention type: DEVICE
Intervention: Ambulatory blood pressure measurement device
Description: Assessment of the 24-h blood pressure profile
Study NCT02291952 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meal schedule
Study NCT00801398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR
Description: Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
Study NCT03521245 — intervention group
Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
Study NCT02291952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal schedule
Study NCT03521245 — intervention group
Intervention type: OTHER
Intervention: Transcriptome analysis
Description: Analysis of RNA-seq data using the Oncobox algorithm.
Study NCT02561975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double pulmonary diffusing
Description: Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~* Alveolar volume (VA)~* Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~* Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc
Study NCT00420524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone/EPO906
Study NCT03423992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cells
Description: chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
Study NCT01305551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablet, Oral, 5 mg, once on Day 1 only
Study NCT03521245 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab
Description: Standard Trastuzumab treatment regimen recommended for breast cancer
Study NCT03521245 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Standard chemotherapy regimen recommended for breast cancer
Study NCT01022099 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Implantation of a Total Knee Arthroplasty
Description: In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides.
Study NCT01305551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablet, Oral, 500 mg, once on Day 1 only
Study NCT03724552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial LED Therapy (Participants ages 9-17)
Description: Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
Study NCT01022099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a Total Knee Arthroplasty
Description: In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides.
Study NCT04305847 — intervention group
Intervention type: OTHER
Intervention: perioperative satisfaction assessment
Description: Satisfaction assessment at 24 and 48 hours post operatively by self-administered survey questionnaire based on different scales: Evan-LR, Net Promotor Score, Satisfaction score.
Study NCT04009395 — intervention group
Intervention type: OTHER
Intervention: Pregnant Women qualitative interviewing
Description: one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
Study NCT04009395 — intervention group
Intervention type: OTHER
Intervention: Midwives qualitative interviewing
Description: one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
Study NCT02329899 — intervention group
Intervention type: OTHER
Intervention: Second step of investigations
Description: Second step according to results of the first step:~* exploration of coagulation factors;~* factor XIII and fibrinolysis investigations;~* investigation of platelet function;~* investigation of thrombocytopenia.
Study NCT02948738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Asthma Education
Description: Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
Study NCT02948738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Asthma Education
Description: Basic review of asthma action plan and inhaler use
Study NCT04198077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
Study NCT04198077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Administered via invasive or non-invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1.0
Study NCT01445080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01445080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01445080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study NCT03724552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial LED Therapy (Participants ages 18-59)
Description: Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm-850nm) is applied to forebrain.
Study NCT02479022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin 320
Description: Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
Study NCT02479022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
Study NCT02479022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
Study NCT02104726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided steroid injection
Description: We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
Study NCT02104726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blind Steroid Injection
Description: Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
Study NCT04364152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task walking training
Description: Participants will be instructed to perform both motor and cognitive dual-task walking during exercise training. For example, for motor dual-task walking, the participants may be instructed to throw and catch a ball while walking. As for cognitive dual-task walking, the participants may be instructed to name animals or perform calculation while walking.
Study NCT00323973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: 10 mg qd
Study NCT00323973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bisoprolol
Description: 10 mg qd
Study NCT01188408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Entrapped Docetaxel (LE-DT)
Description: 110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
Study NCT02063516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Laryngeal Mask
Description: Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
Study NCT02063516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proseal Laryngeal Mask Airway
Description: Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
Study NCT03301194 — intervention group
Intervention type: OTHER
Intervention: RAMP-HT
Description: RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
Study NCT00048542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-Blind Adalimumab/Placebo + MTX
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
Study NCT00048542 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Adalimumab/Placebo + MTX
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
Study NCT00048542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-Blind Adalimumab/Placebo
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
Study NCT00048542 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double-Blind Adalimumab/Placebo
Description: Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
Study NCT00048542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLE BSA Adalimumab +/- MTX
Description: Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
Study NCT00048542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLE FD Adalimumab +/- MTX
Description: Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
Study NCT01305551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin XR FDC
Description: Tablet, Oral, 5/500 mg, once on Day 1 only
Study NCT01213121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: oral tablet/25-600mg per day/once a day/six weeks
Study NCT01582932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% Foam
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
Study NCT04605120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical fusion
Description: 1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft
Study NCT04067687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative home visit
Description: a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
Study NCT04953182 — intervention group
Intervention type: OTHER
Intervention: Pain scale registry
Description: The nurses ask the patient about the pain filling every two hours during the hospitalization.
Study NCT03657745 — intervention group
Intervention type: DEVICE
Intervention: Combination of 40Hz light and cognitive therapy (ALZLIFE)
Description: Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
Study NCT04109326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APAD
Description: 8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment.
Study NCT03226470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T512
Description: T512 suppository contain 500 µg of T512 and suppocire.
Study NCT05436730 — intervention group
Intervention type: DEVICE
Intervention: Sphygmocor
Description: Assessment of the arterial stiffness
Study NCT05436730 — intervention group
Intervention type: DEVICE
Intervention: VaSera-VS
Description: Assessment of the arterial stiffness
Study NCT05436730 — intervention group
Intervention type: DEVICE
Intervention: Somnocheck
Description: Assessment of the sleep breath disturbances
Study NCT01571440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No soluble corn fiber
Description: Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day